Jazz Pharmaceuticals (JAZZ) reported $897.84 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 0.5%. EPS of $1.68 for the same period compares to $2.68 a year ago.

The reported revenue represents a surprise of -8.52% over the Zacks Consensus Estimate of $981.41 million. With the consensus EPS estimate being $4.51, the EPS surprise was -62.75%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Royalties and contract revenues: $58.42 million versus $56.30 million estimated by 10 analysts on average. Revenues- Product sales, net: $839.42 million compared to the $925.39 million average estimate based on 10 analysts. The reported number represents a change of -0.3% year over year. Total revenues- Neuroscience- Oxybate- Xywav: $344.80 million versus the nine-analyst average estimate of $377.35 million. The reported number represents a year-over-year change of +9.4%. Total revenues- Neuroscience- Epidiolex/Epidyolex: $217.74 million versus $233.21 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change. Total revenues- Neuroscience- Sativex: $5.41 million versus the nine-analyst average estimate of $3.79 million. The reported number represents a year-over-year change of +97.7%. Total revenues- Neuroscience- Oxybate (Xywav & Xyrem): $382.05 million versus the nine-analyst average estimate of $415.54 million. The reported number represents a year-over-year change of +0.7%. Total revenues- Neuroscience- Total: $605.19 million versus the nine-analyst average estimate of $652.54 million. The reported number represents a year-over-year change of +4.2%. Total revenues- Oncology- Total: $229.45 million versus $269.04 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -10.9% change. Total revenues- Oncology- Rylaze: $94.23 million versus $104.20 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -8.3% change. Total revenues- Oncology- Defitelio/defibrotide: $40.66 million compared to the $47.89 million average estimate based on nine analysts. The reported number represents a change of -14.7% year over year. Total revenues- Oncology- Vyxeos: $29.54 million versus $34.56 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -7.7% change. Total revenues- Oncology- Zepzelca: $63.03 million versus $80.75 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -16.1% change.

Story Continues

View all Key Company Metrics for Jazz here>>>

Shares of Jazz have returned +10.5% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Jazz Pharmaceuticals PLC (JAZZ):Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments